New Indication Approved for Lyrica Capsules

TOKYO, October 27, 2010 - Today, October 27, 2010, Pfizer Japan Inc. (Head Office: Tokyo, President: Ichiro Umeda, hereinafter "Pfizer") Received approval Thurs replace the Indication of "postherpetic neuralgia" That Is Currently Approved for Lyrica ® Capsules (generic name: pregabalin; hereinafter "Lyrica ®) in Japan with the new and broader Indication of" peripheral neuropathic pain. "

Approval Thurs Produce and distribute Lyrica ® with the Indication postherpetic neuralgia was Received on April 16 of this year, and it was launched on June 22 Pfizer and Eisai Co., LTD.. (Head Office: Tokyo, President: Haruo Naito) are jointly Promoting the drug in Japan and Providing information Regarding the proper usage of the drug.

Lyrica ® is a Therapeutic Agent for the Treatment of Pain Developed by Pfizer Inc. (USA). It has Been Approved in 110 countries and Regions Worldwide (as of July 2010). The drug is recommended by the International Association for the Study of Pain and Other Key Academic Bodies as a first-line Treatment for neuropathic pain. AS ITS Major Mechanism of Action, Lyrica ® is thought Thurs ExpressCard ITS analgesic effect by inhibiting the release of Various neurotransmitters in an overexcited nervous system.

The pathologies and pathogeneses of neuropathic pain are complex and Varied, so it is Considered To Be A form of intractable pain for Which NSAIDs (non-steroidal anti-inflammatory drugs) and Other analgesics EE Can not Be To Have Much Effect.

Lyrica ® has a Mechanism of Action That differs from Those of Conventional analgesic agents, so it is a new option for the Treatment of Pain. Its efficacy and safety Have Been CONFIRMED in Phase III Trials Domestic and Domestic Long-Term Administration Trials Regarding Pain Accompanying Diabetic neuropathy in Addition Thurs postherpetic neuralgia, a typical peripheral neuropathic disease for Which it was Already Approved.

Pfizer Japan Inc. and Eisai Co., LTD.. will use the newly Approved Indication of peripheral neuropathic pain for Lyrica ® Thurs help Improve the Quality of Life of Patients Suffering from pain Accompanying Various types of neuropathic disorders.

-- Press contact --Product Communications, Pfizer Japan Inc.

Telephone: +81-(0)3-5309-6719Public Relations Department, Eisai Co., Ltd.

Telephone: +81-(0)3-3817-5120- Contact for healthcare professionals and consumers regarding Lyrica® (toll-free in Japan) -Product Information Center, Pfizer Japan Inc.

Telephone: 0120-664-467Customer Hotline, Eisai Co., Ltd.

Telephone: 0120-419-497